Privium Fund Management B.V. Fate Therapeutics Inc Transaction History
Privium Fund Management B.V.
- $469 Million
- Q2 2025
A detailed history of Privium Fund Management B.V. transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Privium Fund Management B.V. holds 111,090 shares of FATE stock, worth $102,202. This represents 0.03% of its overall portfolio holdings.
Number of Shares
111,090
Previous 109,026
1.89%
Holding current value
$102,202
Previous $86,000
44.19%
% of portfolio
0.03%
Previous 0.02%
Shares
4 transactions
Others Institutions Holding FATE
# of Institutions
147Shares Held
95.1MCall Options Held
56.7KPut Options Held
5.4K-
Redmile Group, LLC San Francisco, CA12.9MShares$11.8 Million1.07% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$9.31 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.77MShares$8.07 Million0.0% of portfolio
-
Schonfeld Strategic Advisors LLC New York, NY7.79MShares$7.17 Million0.04% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.29MShares$3.95 Million0.0% of portfolio
About FATE THERAPEUTICS INC
- Ticker FATE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 97,000,304
- Market Cap $89.2M
- Description
- Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...